Results 31 to 40 of about 51,514 (235)

Two Cases of Alopecia Universalis

open access: greenProceedings of the Royal Society of Medicine, 1912
E. G. Graham Little
openalex   +4 more sources

Alopecia areata: a multifactorial autoimmune condition [PDF]

open access: yes, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P.   +3 more
core   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

open access: yes, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana   +5 more
core   +2 more sources

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

open access: yes, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran   +2 more
core   +1 more source

Establishing and Prioritising Research Questions for the Treatment of Alopecia Areata: The Alopecia Areata Priority Setting Partnership [PDF]

open access: yes, 2017
BACKGROUND: Alopecia areata is a common hair loss disorder that results in patchy to complete hair loss. Many uncertainties exist around the most effective treatments for this condition. OBJECTIVES: To identify uncertainties in alopecia areata management
Brockley, J.R.   +14 more
core   +2 more sources

Retrospective review of diphencyprone in the treatment of alopecia areata [PDF]

open access: yes, 2015
Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.
Holmes, S., Lamb, R. C., Young, D.
core   +1 more source

Successful treatment of alopecia universalis with abrocitinib: a case report

open access: yesJournal of dermatological treatment (Print), 2023
Abrocitinib, a highly selective inhibitor of Janus kinase 1 (JAK1), has been approved for the treatment of moderate-to-severe atopic dermatitis (AD).
J. Zhang, Y. Zuo
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy